# EDGAR Filing Document

**Accession Number:** 0001485003
**File Stem:** 0001104659-25-121133
**Filing Date:** 2025-12
**Character Count:** 12406
**Document Hash:** b9166783b7a071495072e58939b88833
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-121133.hdr.sgml**: 20251215

**ACCESSION NUMBER**: 0001104659-25-121133

**CONFORMED SUBMISSION TYPE**: S-8 POS

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251215

**DATE AS OF CHANGE**: 20251215

**EFFECTIVENESS DATE**: 20251215

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Carisma Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0001485003
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 262025616
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8 POS
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-217686
- **FILM NUMBER:** 251571713

**BUSINESS ADDRESS:**
- **STREET 1:** 3675 MARKET STREET
- **STREET 2:** SUITE 401
- **CITY:** PHILADELPHIA
- **STATE:** PA
- **ZIP:** 19104
- **BUSINESS PHONE:** 2674916422

**MAIL ADDRESS:**
- **STREET 1:** 3675 MARKET STREET
- **STREET 2:** SUITE 401
- **CITY:** PHILADELPHIA
- **STATE:** PA
- **ZIP:** 19104

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Sesen Bio, Inc.
- **DATE OF NAME CHANGE:** 20180516

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Eleven Biotherapeutics, Inc.
- **DATE OF NAME CHANGE:** 20100223

**As filed with the Securities and Exchange Commission on December 15, 2025** 

**Registration No. 333-195170**

**Registration No. 333-202677**

**Registration No. 333-210523**

**Registration No. 333-217686**

**Registration No. 333-217687**

**Registration No. 333-224959**

**Registration No. 333-231644**

**Registration No. 333-234697**

**Registration No. 333-254264**

**Registration No. 333-255941**

**Registration No. 333-263070**

**Registration No. 333-271103**

**Registration No. 333-286274**

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-195170**

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-202677**

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-210523**

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-217686**

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-217687**

**POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-8 REGISTRATION STATEMENT NO. 333-224959**

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-231644**

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-234697**

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-254264**

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-255941**

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-263070**

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-271103**

**POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-286274**

 ****

***Under***

***The Securities Act of 1933***

**CARISMA THERAPEUTICS INC.** 

**(Exact name of registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Delaware** | **26-2025616** |
| **(State or other jurisdiction of<br> incorporation or organization)** | **(I.R.S. Employer<br> Identification Number)** |
| **3675 Market Street, Suite 401**<br> **Philadelphia, PA** | **19104** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**Amended and Restated 2009 Stock Incentive Plan**

**Amended and Restated 2014 Stock Incentive Plan**

**2014 Employee Stock Purchase Plan**

**CARISMA Therapeutics Inc. 2017 Stock Incentive Plan**

**Inducement Stock Option Awards**

**(Full title of the plan)** 

**Steven Kelly** 

**Interim Chief Executive Officer** 

**Carisma Therapeutics Inc.** 

**3675 Market Street, Suite 401**

**Philadelphia, PA 19104**

**(267) 491-6422**

**(Name, address, and telephone number, including area code, of agent for service)** 

 ****

***Copy to:***

**Brian A. Johnson** 

**Wilmer Cutler Pickering Hale and Dorr LLP**

**7 World Trade Center**

**250 Greenwich Street**

**New York, New York 10007**

**Telephone: (212) 230-8800**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ◻ | Accelerated filer | ◻ |
| Non-accelerated filer | ⌧ | Smaller reporting company | ⌧ |
|  |  | Emerging growth company | ◻ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**DEREGISTRATION OF SECURITIES**

These Post-Effective Amendments (these "<u>Post-Effective Amendments</u>") relate to the following Registration Statements on Form S-8 (each, a "<u>Registration Statement</u>" and collectively, the "<u>Registration Statements</u>") filed by Carisma Therapeutics Inc., a Delaware corporation (previously named Eleven Biotherapeutics, Inc. and Sesen Bio, Inc., the "<u>Registrant</u>"), with the Securities and Exchange Commission (the "<u>SEC</u>") to deregister any and all shares of the Registrant's common stock, par value $0.001 per share ("<u>Common Stock</u>"), registered but unsold or otherwise unissued under each such Registration Statement as of the date hereof:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. Registration Statement on Form S-8 (File No. 333-195170), filed with the SEC on April 9, 2014, registering 67,311 shares of Common Stock issuable under the Registrant's Amended and Restated 2009 Stock Incentive Plan, 35,512 shares of Common Stock issuable under the Registrant's 2014 Stock Incentive Plan (the "<u>2014 Plan</u>") and 7,874 shares of Common Stock issuable under the Registrant's 2014 Employee Stock Purchase Plan (the "<u>2014 ESPP</u>").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Registration Statement on Form S-8 (File No. 333-202677), filed with the SEC on March 12, 2015, registering 36,116 shares of Common Stock issuable under the 2014 Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Registration Statement on Form S-8 (File No. 333-210523), filed with the SEC on March 31, 2016, registering 39,321 shares of Common Stock issuable under the 2014 Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. Registration Statement on Form S-8 (File No. 333-217686), filed with the SEC on May 5, 2017, registering 49,108 shares of Common Stock issuable under the 2014 Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. Registration Statement on Form S-8 (File No. 333-217687), filed with the SEC on May 5, 2017, registering 32,500 shares of Common Stock issuable under Inducement Stock Options granted on September 20, 2016 to certain employees.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. Registration Statement on Form S-8 (File No. 333-224959), filed with the SEC on May 16, 2018, registering 69,405 shares of Common Stock issuable under the 2014 Plan, as amended by Post-Effective Amendment No. 1 to Registration Statement on Form S-8, filed with the SEC on August 10, 2018, deregistering 14,287 of such shares of Common Stock issuable under the 2014 Plan previously registered under the Registration Statement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. Registration Statement on Form S-8 (File No. 333-231644), filed with the SEC on May 21, 2019, registering 55,118 shares of Common Stock issuable under the 2014 Plan and aggregate of 88,750 shares of Common Stock issuable under Inducement Stock Options granted on August 7, 2018 and December 3, 2018 to certain employees.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. Registration Statement on Form S-8 (File No. 333-234697), filed with the SEC on November 14, 2019, registering 395,448 shares of Common Stock issuable under the 2014 Plan and an aggregate of 32,500 shares of Common Stock issuable under Inducement Stock Options granted on August 1, 2019 and September 3, 2019 to certain employees.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. Registration Statement on Form S-8 (File No. 333-254264), filed with the SEC on March 15, 2021, registering 1,650 shares of Common Stock issuable under Inducement Stock Options granted on January 27, 2020 to certain employees.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10. Registration Statement on Form S-8 (File No. 333-255941), filed with the SEC on May 10, 2021, registering 600,000 shares of Common Stock issuable under the 2014 Plan and 115,000 shares of Common Stock issuable under the 2014 ESPP.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11. Registration Statement on Form S-8 (File No. 333-263070), filed with the SEC on February 28, 2022, registering an aggregate of 70,300 shares of Common Stock issuable under Inducement Stock Options granted between March 16, 2021 and January 24, 2022 to certain employees.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12. Registration Statement on Form S-8 (File No. 333-271103), filed with the SEC on April 4, 2023, registering 5,586,568 shares of Common Stock issuable under the Amended and Restated 2014 Stock Incentive Plan (which amended and restated the 2014 Plan), 278,432 shares of Common Stock issuable under the 2014 ESPP and 3,424,522 shares of Common Stock issuable under the Registrant's 2017 Stock Incentive Plan with respect to options assumed by the Registrant pursuant to that certain Agreement and Plan of Merger and Reorganization (as amended), by and among the Registrant, CTx Operations, Inc. (formerly CARISMA Therapeutics Inc.) and Seahawk Merger Sub, Inc.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13. Registration Statement on Form S-8 (File No. 333- 286274), filed with the SEC on March 31, 2025, registering 1,670,004 shares of Common Stock issuable under the Amended and Restated 2014 Stock Incentive Plan (which amended and restated the 2014 Plan).

All share numbers set forth above reflect a 1-for-20 reverse stock split of Common Stock, that became effective on March 7, 2023.

The Registrant has terminated all offerings of its securities pursuant to the Registration Statements. In accordance with an undertaking made by the Registrant in Part II of each Registration Statement to remove from registration by means of a post-effective amendment any securities that had been registered for issuance but remain unsold at the termination of the offering, by filing these Post-Effective Amendments, the Registrant hereby terminates the effectiveness of the Registration Statements and removes from registration any and all securities registered but unsold or otherwise unissued under the Registration Statements, if any, as of the date hereof. The Registration Statements are hereby amended, as appropriate, to reflect the deregistration of such securities. After giving effect to these Post-Effective Amendments, there will be no securities registered by the Company pursuant to the Registration Statements.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Philadelphia, Commonwealth of Pennsylvania, on December 15, 2025.

---

| | |
|:---|:---|
| Carisma Therapeutics Inc. | Carisma Therapeutics Inc. |
| By: | /s/ Steven Kelly |
| Name: | Steven Kelly |
| Title: | Interim Chief Executive Officer |

---

No other person is required to sign these Post-Effective Amendments in reliance upon Rule 478 under the Securities Act of 1933, as amended.